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Abstract
Background: HIV therapeutic vaccination aims to improve the immune responses against HIV in order to control
viral replication without the need for combined antiretroviral therapy (cART). iHIVARNA-01 is a novel vaccine
combining mRNA delivery and T-cell immunogen (HTI) based on conserved targets of effective antiviral T-cell
responses. In addition, it holds adequate stimuli required for activating antigen presenting cells (APC)s and co-
activating specific T-cells (TriMix), including human CD40L, constitutively active TLR4 (caTLR4) and CD70. We
propose that in-vivo targeting of dendritic cells (DCs) by direct administration of a HIV mRNA encoding these
immune modulating proteins might be an attractive alternative to target DCs in vitro.
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Methods/design: This is a phase-IIa, randomized, double-blinded, placebo-controlled, multicenter study in chronically
HIV-1 infected patients under stable cART. One of the three study arms is randomly allocated to subjects. Three
vaccinations with either HIVACAT T-cell immunogen (HTI)-TriMix (iHIVARNA-01), TriMix or water for injection (WFI)
(weeks 0, 2 and 4) are administered by intranodal injection in the inguinal region. Two weeks after the last
immunization (week 6) cART is stopped for 12 weeks. The two primary endpoints are: (1) safety and tolerability of
intranodal iHIVARNA-01 vaccination compared with TriMix or WFI and (2) induced immunogenicity, i.e., increase in the
frequency of HIV-specific T-cell responses between baseline, week 6 and 12 weeks after treatment interruption in
iHIVARNA-01-treated patients as compared to the control groups, immunized with TriMix-mRNA or WFI measured by
an IFNγ ELISPOT assay. Secondary endpoints include the evaluation of time to viral rebound, plasma viral load (pVL) at
w18, the proportion of patients with control of viral load, induction of T-cell responses to new HIV epitopes,
polyfunctionality of HIV-specific T-cells, CD8+ T-cell in-vitro HIV suppressive capacity, the effect on viral reservoir
(measured by proviral DNA and cell-associated RNA), assessment of viral immune escape by mutation and mRNA
expression profiles of host immune genes.
Discussion: This trial aims to direct target DC in situ with mRNA encoding HTI and TriMix for co-stimulation. Intranodal
injection circumvents laborious DC isolation and handling in the laboratory. The trial extends on the safety results of a
phase-I dose-escalating trial. This candidate vaccine could complement or even replace cART for chronic HIV infection
and could be applicable to improve the care and cost of HIV infection.
Trial registration: EudraCT 2016-002724-83 (22 September 2016); ClinicalTrials.gov, ID: NCT02888756. Registered on 23
August 2016.
Keywords: HIV-1, Therapeutic vaccine, Functional cure, Immunotherapy, Reservoir, Lymph node, TriMix, Antigen-
presenting cell
Background
Worldwide, an estimated 37 million people are infected
with the human immunodeficiency virus (HIV) [1]. HIV is
a single-stranded, positive-sense ribonucleic acid (RNA)
virus of the genus Lentivirus. The virus infects human
CD4+T-cells but also various mononuclear myeloid cells,
including dendritic cells (DCs), monocytes/macrophages.
It integrates into the host genome after reverse transcrip-
tion to double-stranded deoxyribonucleic acid (DNA). In
untreated patients, the infection progresses to acquired
immunodeficiency syndrome (AIDS) – as characterized
by a decline in CD4+ T-cells [2]. In 2015, an estimated
17.5 million people worldwide received combined anti-
retroviral therapy (cART) [1]. Despite being very effective
at stabilizing the HIV infection and preventing virus trans-
mission, cART has several disadvantages, including short-
and long-term side effects. The therapy cannot eradicate
HIV and, therefore, has to be maintained for life [3]. As a
consequence, HIV therapy is costly to maintain. Further-
more, both therapy distribution and adherence are a chal-
lenge for patients and physicians – in both developing as
well as developed countries [4]. Therefore, there is a clear
unmet need for cost-effective and viable non-drug-based
treatment in HIV-infected individuals.
Therapeutic vaccination has emerged as a strategy
which aims to improve the immune responses against
HIV in order to control viral replication without the
need for cART [5]. To date, numerous immunogens,
administration routes and vaccination strategies have
been employed, so far with only limited success [5–8].
Garcia and colleagues obtained promising results in a
strategy known as “ex-vivo modification of DCs” [8].
HIV-infected patients were administered autologous
DCs pulsed with whole, inactivated HIV particles. This
DC-based vaccine offers a promising strategy by using
the ability of DCs to take up and present antigens to
CD4+ and CD8+ T-cells. The immune responses act
against viral replication by lysing HIV-infected cells.
However, a functional cure (i.e., undetectable HIV
plasma viral load, i.e., < 50 copies/mL) was not achieved.
Furthermore, ex-vivo modification of DCs is a technical
and labor-intense strategy.
The iHIVARNA-01 is intended for therapeutic vaccin-
ation of HIV-1-infected patients. It is a combination of
mRNA sequences that aim to provide (1) an effective
HIV immunogen to induce T-cell responses against rela-
tively conserved, vulnerable portions of the virus, re-
ferred to as HIVACAT T-cell immunogen (HTI) as well
as (2) adequate stimuli required for activating APCs and
co-activating specific T-cells (TriMix). The former is de-
signed to induce T-cell responses with specificities asso-
ciated with superior HIV control in vivo and covering a
wide range of HLA class I- and class II-restricted,
HIV-derived epitopes [9]. The TriMix portion provides
activation molecules to enhance T-cell activation and
antigen presentation by DCs. The mRNA sequences
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correspond to human CD40L, constitutively active TLR4
(caTLR4) and CD70 [10]. iHIVARNA-01 investigational
product (refer to section “Methods/design”) is the result
of the iHIVARNA phase-1 clinical trial. In 2016, 21
HIV-infected volunteers were recruited in Hospital
Clínic in Barcelona. Subjects received mixed ratios of
TriMix:HTI and TriMix solutions, up to 1200 μg (900 μg
HTI + 300 μg TriMix).1
Methods/design
Primary and secondary objectives
This study will evaluate the safety, tolerability and im-
munogenicity of iHIVARNA-01. The primary objectives
are to evaluate:
 the safety and tolerability of intranodal iHIVARNA-
01 vaccination compared with TriMix-mRNA or
placebo, focusing on the nature, frequency and se-
verity of local adverse events (pain, cutaneous reac-
tions including induration) and systemic adverse
events (temperature, chills, headache, nausea, vomit-
ing, malaise and myalgia)
 the immunogenicity of an immunization schedule
with HTI-TriMix (iHIVARNA-01) to increase the
frequency of HTI-specific T-cell responses between
baseline and 2 and 14 weeks after the last injection
(i.e., weeks 6 and 18 of the study) as compared to
the control groups, immunized with TriMix-mRNA
only or placebo
The secondary objectives are to evaluate:
 the magnitude and the kinetics of the HIV-specific
CD4+ and CD8+ T-cell responses generated by the
immunization schedule in the three groups by two
methods (ELISPOT, intra-cellular cytokine staining
– ICS) at baseline and at weeks 6 and 30
 the ability of the immunization schedules to prolong
time until viral rebound after discontinuation at
week 6 as compared to control groups TriMix or
placebo
 the suppressive effect on plasma viral load in vivo
after analytical treatment interruption (ATI) from
week 6 to week 18 compared to two control groups,
receiving TriMix only or placebo
 the proportion of patients with control of viral load
below detectable level 12 and 24 weeks after start of
ATI (functional cure)
 the percentage of patients who generate a vaccine-
induced immune response to new HIV epitopes
present in the HTI sequence
 induction or enhancement of the CD8+ T-cell in-
vitro HIV-suppressive capacity
 the effect on reservoir as measured by proviral DNA
and the cell-associated viral RNA (unspliced and
multiple spliced viral RNA)
 viral immune escape by sequencing of HIV and to
conduct sieve-effect analyses in rebounding virus
after cART interruption
 host protein mRNA expression profiles in whole
blood at baseline and week 6 and week 18
 storage of fecal samples for future exploratory
analysis of gut microbiota composition and diversity
Study design, treatment arms and stages
This is a phase-IIa, randomized, double-blinded, placebo-
controlled outpatient-clinic-based multicenter study in
chronically HIV-1 infected patients under stable cART. En-
rolled and randomized patients will be treated in one of the
three study arms, comprising two stages.
Stage I consists of an immunization period from week
0 to week 6, while on cART. The immunization is done
by an intranodal injection in a prominent lymph node in
the inguinal region. The study arm (verum –
HTI-TriMix (iHIVARNA-01) n = 40, control – TriMix
n = 15 and placebo – water for injection (WFI) n = 15) is
randomly allocated and stratified per center. An injec-
tion is given at weeks 0, 2 and 4. Stage II consists of the
post-immunization and analytical treatment interruption
(ATI) period (cART is stopped) and lasts from week 6 to
week 18. Patients with an undetectable viral load at week
18 will remain off cART up to week 30. Study end is at
week 30. In case a patient still has an undetectable (< 50
copies/mL) viral load, they may continue cART interrup-
tion in consultation with the treating physician. cART
can be re-initiated for medical reasons at any time and/
or if the CD4+ T-cell counts drop below 50% of baseline
or below 350 cells/mL.
Refer to Fig. 1 for a visual overview of the stages and
treatment arms.
Inclusion and exclusion criteria
To be eligible to participate, a patient must meet all of
the following criteria (inclusion criteria):
1. Age ≥ 18 years of age
2. Voluntarily signed informed consent
3. Proven HIV-1 infection (with documented anti-
bodies against HIV-1 and a detectable plasma HIV-
1 RNA before initiation of therapy)
4. On stable treatment with cART regimen
(antiretroviral therapy consisting of at least three
registered antiretroviral agents) for at least 3 years
5. Nadir CD4+ ≥ 350 cells/μL (up to two occasional
determinations ≤ 350 cells/μL are allowed)
6. Current CD4+ cell count ≥ 450 cells/μL
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7. HIV-RNA below 50 copies/mL in the last 6 months
prior to randomization, during at least two
measurements (occasional so called “blips” ≤ 500
copies/mL are permitted)
8. If sexually active, willing to use a reliable method of
reducing the risk of transmission to their sexual
partners during treatment interruption (including
PrEP)
(a). For heterosexually active women, using an
effective method of contraception with partner
(combined oral contraceptive pill; injectable or
implanted contraceptive; IUD/IUS; consistent
record with condoms; physiological or
anatomical sterility (in self or partner) from 14
days prior to the first vaccination until 4 months
after the last vaccination
(b).For heterosexually active men, using an effective
method of contraception with their partner
from the first day of vaccination until 4 months
after the last vaccination
Patients who meet any of the following criteria will be ex-
cluded from participating in the study (exclusion criteria):
1. Treatment with a non-cART regimen prior to the
cART regimen
2. Previous failure to antiretroviral and/or mutations
conferring genotypic resistance to antiretroviral
therapy
3. Non-subtype B HIV infection
4. Active hepatitis B virus and/or hepatitis C virus co-
infection
5. History of a CDC class C event [11];
6. Pregnant woman (screened with a positive
pregnancy test), lactating or intending to become
pregnant during the study
7. History of malignancy ≤ 30 days (extended period
on the clinical assessment of the investigator) prior
to screening
8. Active infection with fever (38 °C or above) ≤ 10
days of screening and/or first vaccination
9. Therapy with immunomodulatory agents (e.g.,
systemic corticosteroids), including cytokines (e.g.,
IL-2), immunoglobulins and/or cytostatic chemo-
therapy ≤ 90 days prior to screening. This does not
include seasonal influenza, hepatitis B and/or other
travel-related vaccines
10. Congenital, acquired or induced coagulation
disorders, such as thrombocytopenia (thrombocytes
< 150 × 109/L) and/or current use of anti-coagulant
medication (e.g., coumarins, inhibitors of Xa); usage
of nonsteroidal anti-inflammatory drugs (NSAIDs)
(including acetylsalicylic acid) is allowed; however,
it is advised to interrupt therapy 10 days ahead of
vaccination
11. Usage of any investigational drug ≤ 90 days prior to
study entry
12. An employee of the investigator or study site, with
direct involvement in the proposed study or other
studies under the direction of that investigator or
Fig. 1 Overview of the study period, interventions and assessments
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study site, or is a family member of an employee or
the investigator
13. Any other condition, which, in the opinion of the
investigator, may interfere with the evaluation of
the study objectives
Study procedures: informed consent and screening
Refer to Fig. 1 for a full overview of the study period, inter-
ventions and assessments. The study procedures according
to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Statement [12] are shown in
Fig. 2 and are available as Additional file 1. The investiga-
tional medicinal product (IMP) in this study is
iHIVARNA-01. In each center, their HIV treating physi-
cians will inform patients about the phase-IIa clinical trial
and confirm their eligibility. Those interested will receive a
hardcopy/digital version of the patient information form
(PIF) and are invited for the informed consent and screen-
ing visit, at most 8 weeks prior to eventual enrollment. The
study will be discussed in detail and any questions will be
answered. Specific attention applies for heterosexually ac-
tive women: an effective method of contraception with their
partner from 14 days prior to the first vaccination until 4
months after the last vaccination will be demanded. For
heterosexually active men, using an effective method of
contraception with their partner from the first day of vac-
cination until 4months after the last vaccination will be
demanded. The investigator repeats the former during
follow-up visits in case of enrollment and actively ques-
tions the patients (or partner) adherence to these
protocol-dictated life rules. Attention will be paid to risks
of viral rebound syndrome and adequate measures for risk
reduction of virus transmission during ATI will be dis-
cussed. An optional consideration period of up to 2 weeks
is offered. The principal investigator (PI) (or their desig-
nated collaborator) will obtain written informed consent.
Patients undergo a clinical examination and blood will be
drawn. Demographic data, medical history and concomi-
tant medication are recorded (refer to Fig. 2).
Study procedures: enrollment and vaccinations
Review of screening data will be performed according to
the inclusion and exclusion criteria. Female patients
undergo a pregnancy test (repeated prior to each vaccin-
ation), which should return negative in order to continue
with study participation. When the former criteria are
met, a patient will be enrolled to the study. The investi-
gator blindly assigns the patient to one of the treatment
groups by allocating the next free randomization code
for the clinical site to the patient. This randomization
code list was generated by an independent statistician
prior to start of the study (using R: A language and en-
vironment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria). The label con-
taining the randomization code was attached to the ap-
propriate IMP at the central production facility in order
Fig. 2 Screening, assessments and interventions schedule for iHIVARNA phase IIa. 1 screening at most 8 weeks prior to enrollment at W0. Interval
of 4 to 2 weeks is advised and optional consideration period of up to 2 weeks is offered. 2 F full visit, L laboratory alone, P phone call. 3 full
physical examination vs. vitals/lymph nodes alone. A full physical examination must be performed during follow-up when clinically indicated. 4
applicable to female subjects (reproductive age and not anatomically sterilized). Intranodal injection and treatment interruption is only allowed
after a negative pregnancy test. 5 laboratory tests for safety includes hemoglobin, hematocrit, leucocytes, antibodies. Neutrophil count,
thrombocytes, creatinine, aspartate aminotransferase (ASAT), alanine transaminase (ALAT), gamma-glutamyl transpeptidase (GGT), alkaline
phosphatase (ALP), total bilirubin, amylase (or lipase), creatine kinase (CK, known as creatine phosphokinase), glucose, CD4+ and CD8+ cells and
HIV viral load. 6 follow-up of vital signs (RR/pulse) at 5 min and 60 min after injection. 7 cART treatment interruption (ATI) starting from week 6 up
to week 18. When there is an undetectable viral load at week 18, ATI is continued until week 30. Schedule according to template available from
SPIRIT Statement,© 2013 Chan et al. [12]
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to keep the blind for both the sponsor and investigators.
The IMP is administered using ultrasound guidance by a
radiologist sufficiently trained in ultrasound imaging and
tissue biopsies. Injections will be given alternated be-
tween the right and left prominent inguinal lymph node.
Patients will be monitored during the first hour after
immunization by recording vital signs (pulse, blood
pressure and respiratory rate) on the case record form
(CRF), as well as any local reactions and systemic events
(refer to Table 1). A diary card (refer to Tables 2 and 3)
will be given to all the subjects, with written instructions
and a verbal explanation to record local and systemic ad-
verse events following 1 week after immunization. The
diary is also used to track all medication (including
over-the-counter ones) usage in the same period. Using
a standardized letter, the treating general practitioner of
the patient is informed of the study participation. Active
reporting of eventual adverse events and/or the prescrip-
tion of concomitant medication is demanded by inform-
ing the investigator without further due delay. Trial
participation is mentioned in the electronic patient files,
in such a way that other healthcare professionals are able
to contact the study team for consultation or reporting
of (serious) adverse events. The study team will hold a
telephone call with patients 7 days (± 2 days) after the
first immunization. This contact will inquire about ad-
verse events, both local and systemic. Additional visits
may be recommended at the discretion of the clinical
and principal investigators. Assessments and vaccina-
tions are repeated as described above at week 2 and
week 4. Short visits are scheduled in between for blood
draw to be able to answer the study’s objectives.
Study procedures: analytical treatment interruption (ATI),
restart and final visit
Two weeks after the third vaccination (week-6 visit),
cART will be interrupted. Female subjects will only be
allowed interruption after a negative pregnancy test. In
the visits at weeks 8, 10, 14, 18, 24 and 30, information on
concomitant medication, a physical examination and la-
boratory tests (refer to Fig. 2) are obtained. At week 18,
cART will be reinitiated unless a patient shows a stable
undetectable viral load. Patients that have not resumed
cART at week 30 (study end) because their plasma viral
load remains undetectable and it is their preference not to
re-initiate cART, should be closely monitored for plasma
viral load and CD4+ cell counts on an (advised) 8-weekly
base by their treating physicians.
Study procedures: emergency and relevant considerations
regarding ATI
In case of a medical urgency, revealing the study arm (i.e.,
unblinding) is possible by contacting unblinded pharmacy
personnel at the sponsor’s pharmacy. This service is avail-
able 24 h a day. In case of accidental IMP breakage, loss,
temperature excursions, etc., backup IMP is available at
the study sites. The investigator can use a backup IMP vial
by enquiring about the correct backup vial code at the
pharmacy of the sponsor. Since this pharmacy has an un-
blinded list, the correct backup code can be issued.
ATI is needed in the search for an HIV cure [13]. During
ATI patients will be monitored for adverse events of
plasma viral rebound such as fever, fatigue, lymphadenop-
athy, pharyngitis, rash and/or weight loss. If the CD4+
T-cell counts drop below 50% of baseline level or below
350 cells/mL, an extra CD4+ T-cell count will be per-
formed within 7 days. If the results are below 50% of base-
line or below 350 cells/mL, cART will be re-initiated
immediately. cART will also be re-initiated if the physician
or investigator judges that this is in the best interest of the
patient. A patient will prematurely discontinue the study
in case of withdrawal of informed consent or if the investi-
gator considers it to be in the best interest of the patient
to withdraw. If a female participant becomes pregnant
during the study, she will discontinue the study treatment
(i.e., vaccination), but will be asked for consent for the
pregnancy and delivery follow-up. Treatment will not be
interrupted in these patients. In case a patient withdraws
from the study, all efforts will be made to complete the
week-30 assessments as the termination visit.
Study procedures: reporting to authorities and temporary
halt or suspension
According to the regulations of the European Union and
as dictated by Dutch governmental law serious adverse
events (SAEs) will be reported to the accredited Ethical
Committee (EC) that approved the study within a period
of maximum 15 days after the sponsor has first
Table 1 Overview of assessments shortly after intranodal vaccination
Assessment Options
Vaccination side Left, right, not performed
Visual inspection of vaccination site No abnormalities, erythema, blisters, other …
Echo-guided inspection of vaccination site No abnormalities, pathological enlarged lymph node (… mm), other …
Time of vaccination hh:mm
Vaccination in middle of lymph node With certainty in middle, doubtful
Physical examination 5 and 50–70 min after procedure Respiratory rate (RR) and pulse rate/min.
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knowledge of the SAE. SAEs that results in death or are
life-threatening will be reported within 7 days. Suspected
unexpected serious adverse reactions (SUSARs) that
have arisen in this trial (and, when applicable, other tri-
als from the same sponsor or with the same study prod-
uct) will be reported via an online portal. All SUSARs
will be submitted in a line-listing twice a year. An annual
safety report of SAEs and safety analysis will be submit-
ted to the ECs and competent authorities. The sponsor
will suspend the study if there is sufficient ground sug-
gesting that continuation of the study will jeopardize pa-
tient health or safety. A Data Safety Monitoring Board
(DSMB), an independent group of experts, advises the
sponsor and will at least meet on four occasions prior to
and during the study.
Study endpoints
Refer to “Primary and secondary objectives” above.
Statistical analysis including sample size calculation
Analysis will be performed using an intention-to-treat
approach. Assuming a standard deviation of 0.5log10 in
the change from baseline of cumulative frequencies of
HTI-specific PBMC, a type 1 error of 5%, a power of
90%, as determined by a two-sided, non-parametric test
(Mann-Whitney, 15% additional subjects), taking into
account the weighting for case group ratio of more than
2:1, a sample of 40 in the HTI-TriMix arm and 15 in
each control arm will allow to detect a difference of at
least 0.7log10 between any HTI-TriMix arm and the con-
trols arms, allowing for 10% of non-assessable patients.
Discussion
In the challenging research field of HIV immunotherapy,
we use the iHIVARNA-01 candidate vaccine in the search
for cure. The strategy of the iHIVARNA consortium con-
sists of a DC-based approach by intranodal administration
of a newly developed HIV immunogen (HTI) and TriMix.
Many of the immunotherapy strategies so far have relied
on immunogens that cover regions of the virus that are
frequently targeted by the immune system in the majority
of chronic HIV-infected patients. These immune re-
sponses, even when enhanced, in general do not prevent
disease progression [6, 14]. HTI is the result of a detailed
investigation into effective antiviral T-cell responses and
their fine specificity and aims to induce T-cell responses
of high functional avidity and higher suppressive capacity
towards vulnerable sites of HIV [9, 15].
In addition, co-stimulatory molecules are delivered in
the formula of TriMix, consisting of CD40L, CD70 and
TLR4a mRNA. TriMix was used in several trials, showing
promising results in the field of tumor immunology [10,
16, 17] – including unpublished data; NCT 01302496,
NCT01066390, NCT01530698. The rationale to provide
extra immunomodulatory signals in the search for HIV
cure was proven in a recent preclinical trial in SIV-
Table 2 Patient diary, general symptoms
Grade 1:
mild
Grade 2:
moderate
Grade 3:
severe
Grade 4:
extreme
Chills/rigors Mild hot/cold flushes requiring blanket or
occasional painkillers/antipyretics
Limiting daily activity > 6 h or need
regular painkillers/antipyretics
Uncontrollable shaking, treatment
from doctor needed
Hospitalization
Malaise/
tiredness
Normal activity reduced – not bad
enough to go to bed
Fatigue such that 0.5 days in bed for
1 or 2 days
Fatigue such that is in bed all day
or 0.5 day for more than 2 days
Hospitalization
General
muscle
aches
No limitation of activity Muscle tenderness, limited activity,
e.g., difficulty climbing stairs
Severe limitation, e.g., cannot climb
stairs
Hospitalization
Headache No treatment or responds to usual
treatment like paracetamol
Occasional treatment like
paracetamol needed
Strong pain killers needed (with
prescription)
Hospitalization
Nausea Intake maintained Intake reduced at most 3 days Minimal intake 3 days or more Hospitalization
Vomiting Less than 4 × a day or lasting less than 1
week
At least 4 x a day or lasting 1 week
or more
Unable to keep any food of fluids
down
Hospitalization
General symptoms are scored on a grade 1–4 scale at 12 h and 24 h post immunization. This is repeated every 24 h up to and including day 7
Table 3 Patient diary, local reactions
Grade 1:
mild
Grade 2:
moderate
Grade 3:
severe
Grade 4:
extreme
Pain at injection site (including ache)
but not skin discomfort
No treatment or responds to
occasional treatment
Partial response to
treatment
Need to use regular treatment to
control pain
Hospitalization
Itching or irritation in the skin at site of
injection
No treatment or responds well to
treatment prescribed
Partial response to
treatment
Need to use regular treatment to
control symptoms
Hospitalization
Local reactions at the injection site (pain, itching) are scored on a grade 1–4 scale at 12 h and 24 h post immunization. This is repeated every 24 h up to and
including day 7. In case there is any redness, fluid-filled blisters, blood-fluid blisters or hard swelling of the skin, the patient is instructed to measure and note
their diameter in centimeters
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infected macaques, where coincident Ad26/MVA vaccin-
ation and TLR7 agonist administration led to better im-
mune stimulation of both the innate and cellular systems.
This resulted in a delay in viral rebound and lower plasma
viral load when cART was interrupted [18].
Concerning the administration of the vaccine, iHI-
VARNA was designed to target DCs. Promising results
were achieved in former studies where autologous DCs
were loaded ex vivo, with inactivated virus or electropo-
rated with mRNA-encoding HIV proteins [19]. The
current study thus circumvents this laborious DC isola-
tion and handling in the laboratory by direct intranodal
vaccination in the inguinal region. The use of naked
mRNA bypasses recombinant vectors and their regula-
tory issues. However, this is only a proof-of-concept trial
and studies currently are testing the stability of mRNA
and targeted delivery, e.g., via chemical modifications
and embedding in particles [20–23]. The goal will be to
develop a vaccine that can be used from the fridge or
even off the shelf (stored at room temperature) and that
will target DCs after in-vivo administration.
The iHIVARNA phase-I, open-label, dose-escalation
trial (NCT02413645) proved that this IMP is safe and
well tolerated in HIV-1-infected patients on cART. The
iHIVARNA phase IIa, is designed as a randomized,
placebo-controlled, double-blinded trial. The three-arm
design comprises (A) the full IMP (HTI and TriMix), (B)
a placebo consisting of TriMix alone and (C) a placebo
consisting of injection fluid. Arm B is important to be
able to distinguish effects of general immune activation
by TriMix from the effects of the full vaccine with the
HIV-specific immunogen.
The trial will evaluate the safety and immunogenicity of
iHIVARNA-01 in chronically HIV-infected patients under
stable combined antiretroviral therapy and includes an
analytical treatment interruption. Besides these primary
endpoints, several secondary endpoints will be evaluated.
The commonly known T-cell ELISPOT essay is extended
with analysis of multiple cytokine expression after in-vitro
stimulation [9, 24]. Also, an ELISPOT assay relying
in-vitro re-stimulation with autologous B-cells expressing
the vaccine immunogen is planned [25, 26]. This should
give us a more comprehensive picture of the immune re-
sponses induced upon vaccination. An established virus
suppression assay to test the in-vitro activity of patient-de-
rived CD8+ T-cells on virus production by super-infected
autologous CD4+ T-cells is available [27]. Beside the spe-
cific immune reactions, innate immune signatures will be
monitored by transcriptome analysis, as this has shown in-
formative in a previous trial [28].
Control of in-vivo viral replication will be studied after
analytical treatment interruption and different endpoint
approaches will be considered, i.e., time to viral rebound,
levels of pVL and the proportion of patients with
undetectable viremia after 12 weeks of treatment inter-
ruption. Effects on the viral reservoir will be measured
with various assays during the immunization period, in-
cluding ultra-sensitive plasma virus polymerase chain re-
action (PCR) and PCR-based approaches to measure cell
associated viral RNA and DNA. In case of viral rebound,
the evolution of the virus will be followed with deep se-
quencing to evaluate mechanisms of immune escape
and/or a potential sieve effect on the rebounding viral
populations after the immunotherapy [29]. These results
may indicate either an advantageous effect, if the viral
and proviral loads decrease and the virus mutates to a
less fit population. On the other hand, we might observe
escape from the vaccine-induced immune pressure,
without a gross effect on viral burden.
To summarize, the trial has a comprehensive set of as-
says that will be used to establish the effects of the im-
munotherapy in vitro and in vivo. If this candidate
would be able to obtain the functional cure in at least a
proportion of patients it could be complementary to
cART or even replace cART and would improve the
overall care and cost of HIV-1 infected patients.
Trial status
Recruiting patients since 27 March 2017.
Endnote
1During the revision process of this paper, it became
apparent that the study product iHIVARNA-01 contains
an error in that the RNA sequence contained by mistake
a second start codon in front of the HTI immunogen
coding sequence. This error is likely to influence the ex-
pression of the HTI protein, from the mRNA vaccine. Even
though the degree to which this impacted the expression of
HTI remains unclear, the results of the preclinical trial
show that there is sufficient expression for the induction of
an immunogen-specific T-cell response in mice.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist populated for for iHIVARNA
phase IIa. (DOC 120 kb)
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